AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01930643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
Study NCT00590993 — intervention group
Intervention type: OTHER
Intervention: MRI and MRSI
Description: Compare treatment impact when using MRI and MRSI
Study NCT01581879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Hydrochloride
Description: Ziprasidone HCL Capsules, 20 mg
Study NCT01426906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
Study NCT01426906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
Study NCT03405662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vielight Neuro Gamma
Description: The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
Study NCT03405662 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Vielight Neuro Gamma
Description: The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
Study NCT03383185 — intervention group
Intervention type: DEVICE
Intervention: Intrauterine device
Description: Use of Intrauterine device during the follow-up period
Study NCT03383185 — intervention group
Intervention type: DRUG
Intervention: Combined Oral Contraceptive
Description: Use of combined oral contraceptive during the follow-up period
Study NCT03383185 — intervention group
Intervention type: DRUG
Intervention: Progestin-only pills
Description: Use of progestin-only pills during the follow-up period
Study NCT03383185 — intervention group
Intervention type: DRUG
Intervention: Depot-Medroxyprogestereone Acetate
Description: Use of depot-medroxyprogesterone acetato during the follow-up period
Study NCT00432575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surinabant (SR147778)
Description: oral administration
Study NCT03735498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: Promote effective coping and reduce caregiving burden
Study NCT03773653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMT to be combined with BAT
Description: Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
Study NCT03773653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMT to be combined with MT
Description: Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
Study NCT03773653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMT to be combined with IOT
Description: Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
Study NCT04566731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
Study NCT04566731 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
Study NCT00432575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT00581256 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
Study NCT00581256 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D
Description: All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
Study NCT01196104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Study NCT01196104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Usual Care
Study NCT01196104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Study NCT01196104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Study NCT02478086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: use amine acids parenteral 3.5g
Description: Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet.
Study NCT02478086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: use amine acids parenteral 4g
Description: Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet.
Study NCT01720797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
Study NCT01720797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthestic
Description: Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
Study NCT01720797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
Study NCT01720797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chlorhexidine
Description: Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
Study NCT00176865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant
Description: IV on Day 0
Study NCT00176865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30mg/m\^2 IV Day -7 through Day -3
Study NCT02784262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botox injection Multiguide
Description: botox injection under CT/MR navigation and with the navigation tool MultiGuide
Study NCT02183727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-C Ligament
Description: The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
Study NCT04566731 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Modified Contraint-Induced Language Therapy (mCILT)
Description: Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
Study NCT04566731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Contraint-Induced Language Therapy (mCILT)
Description: Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
Study NCT04183517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5382A
Description: Orally once daily or twice daily
Study NCT03207334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant.
Study NCT03207334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle.
Study NCT02106039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive monitoring
Study NCT03810820 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)
Description: A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
Study NCT00176865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 140 mg/m\^2 IV Day -1
Study NCT00176865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Description: 30 mg/kg IV Day -5 through Day -1
Study NCT00176865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath 1H
Description: 0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
Study NCT00176865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children \<40 kg) maintaining a level of >200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
Study NCT00176865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
Study NCT02183727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring Autograft
Description: The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
Study NCT04982523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mental Health Program
Description: The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
Study NCT02565836 — intervention group
Intervention type: DRUG
Intervention: fixed-dose activated prothrombin complex concentrate
Description: FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated
Study NCT02565836 — intervention group
Intervention type: DRUG
Intervention: variable-dose inactivated prothrombin complex concentrate
Description: Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated.
Study NCT01537718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REPLY 200
Description: REPLY 200 pacemaker
Study NCT04206462 — intervention group
Intervention type: OTHER
Intervention: Questionnaire of eating habits
Description: frequency and type of aliments
Study NCT04133311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-130A
Description: Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
Study NCT04133311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan®
Description: Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
Study NCT04133311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DE-130A/DE-130A
Description: After Week 12, received DE-130A continuously.
Study NCT04133311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xalatan®/DE-130A
Description: From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
Study NCT01820962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: when not in use CVCs are locked with heparin
Study NCT01820962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concentrated citrate
Description: when not in use the CVC is locked with concentrated citrate
Study NCT02919462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Description: Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
Study NCT02919462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
Study NCT02919462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance with Metronomic Oral Vinorelbine
Description: Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
Study NCT02919462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
Study NCT02919462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
Study NCT02919462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance with Pemetrexed
Description: Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
Study NCT00809705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc once weekly for 12 weeks
Study NCT00809705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
Study NCT00809705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly for 12 weeks
Study NCT01057368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Day of intensive meditation practice
Description: Long-term meditators practice for \~6 hours of meditation at each time point
Study NCT01057368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: 8-week class designed to enhance well-being through training in mindfulness meditation
Study NCT01057368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: 8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
Study NCT04034277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Therapy
Description: LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
Study NCT04034277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: speech rehabilitation protocol comprehend:~* Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~* Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation.
Study NCT03340545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Custom Magnetic Resonance Elastography Device
Description: Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.